XL 820

Drug Profile

XL 820

Alternative Names: XL-820

Latest Information Update: 27 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Platelet-derived growth factor inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastrointestinal stromal tumours; Solid tumours

Most Recent Events

  • 17 Dec 2008 Discontinued - Phase-I for Solid tumours in USA (PO)
  • 23 Oct 2008 GlaxoSmithKline decides not licence XL 820
  • 25 Jul 2007 Patient recruitment into a phase I trial of once-daily XL 820 in patients with solid tumours is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top